Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Data from a late-stage trial of the most advanced of a new class of drugs targeting the hepatitis C virus protease fuel hopes for major improvements in treatment outcomes.
From branded generics to drugs developed specifically for patients in Asia, Bethan Hughes investigates the strategies that large-cap pharmaceutical companies are pursuing to meet the medical needs of emerging markets.
